More doubts cast over AstraZeneca vaccine
The US infectious diseases agency says trial efficacy data for the COVID-19 vax may be 'incomplete'
AstraZeneca may have provided an incomplete view of efficacy data on its COVID-19 vaccine from a large scale US trial, says the country’s National Institute of Allergy and Infectious Diseases (NIAID), in a fresh setback to the vaccine.
AstraZeneca said on Monday its COVID-19 vaccine developed with Oxford University in the UK was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru.
